The antiprotozoal drug pentamidine ameliorates experimentally induced acute colitis in mice by Giuseppe Esposito et al.
RESEARCH Open Access
The antiprotozoal drug pentamidine ameliorates
experimentally induced acute colitis in mice
Giuseppe Esposito1*, Elena Capoccia1, Giovanni Sarnelli2, Caterina Scuderi1, Carla Cirillo2,3, Rosario Cuomo2
and Luca Steardo1
Abstract
Background: Intestinal inflammation is partly driven by enteroglial-derived S100B protein. The antiprotozoal drug
pentamidine directly blocks S100B activity. We aimed to investigate the effect of pentamidine on intestinal
inflammation using an animal model of dextran sodium sulphate (DSS)-induced acute colitis.
Methods: Mice were divided into: control group, colitis group (4% DSS for four days) and two pentamidine-treated
colitis groups (0.8 mg/kg and 4 mg/kg). Anti-inflammatory effect of pentamidine was assessed in colonic tissue by
evaluating the disease activity index and the severity of histological changes. Colonic tissue were also used to
evaluate cyclooxigenase-2, inducible nitric oxide synthase, S100B, glial fibrillary acidic protein, phosphorylated-p38
MAPkinase, p50, p65 protein expression, malondyaldheyde production, mieloperoxidase activity, and macrophage
infiltration. Nitric oxide, prostaglandin E2, interleukin-1 beta, tumor necrosis factor alpha, and S100B levels were
detected in plasma samples. Parallel measurements were performed in vitro on dissected mucosa and longitudinal
muscle myenteric plexus (LMMP) preparations after challenge with LPS + DSS or exogenous S100B protein in the
presence or absence of pentamidine.
Results: Pentamidine treatment significantly ameliorated the severity of acute colitis in mice, as showed by
macroscopic evaluation and histological/biochemical assays in colonic tissues and in plasma. Pentamidine effect on
inflammatory mediators was almost completely abrogated in dissected mucosa but not in LMMP.
Conclusions: Pentamidine exerts a marked anti-inflammatory effect in a mice model of acute colitis, likely targeting
S100B activity. Pentamidine might be an innovative molecule to broaden pharmacological tools against colitis.
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Background
Although the etiology of ulcerative colitis (UC) remains
incompletely understood, severe and persistent mucosal
infiltration of macrophages and neutrophils in the large
intestine represents a prominent feature [1]. Immune
cells release cytokines, interleukins and proinflammatory
signaling molecules [2-4]. In addition to the well-known
involvement of macrophages and neutrophils, other cell
types have been recently reported to substantially con-
tribute to the onset and progression of the disease. En-
teric glial cells (EGC) play a fundamental role in the
maintenance of gut homeostasis since they have trophic
and protective functions toward enteric neurons and are
fully implicated in the modulation of neuronal activities
[5]. Moreover, EGC have been repeatedly reported to trig-
ger and support intestinal inflammation [6] and to function
as a first line of defense against pathogens [7]. EGC may
proliferate and be activated in response to injury and in-
flammation undergoing reactive gliosis (enterogliosis), a
condition in which they release neurotrophins, growth fac-
tors and proinflammatory cytokines cross-talking with
other infiltrating immune cells [8]. Alterations in the
homeostasis of the enteric nervous system are induced by
reactive enterogliosis and are characterized by the massive
overexpression and secretion of specific astroglial-derived
signaling molecules such as S100B protein [9,10].
S100B is a diffusible, Ca++/Zn++-p53 binding protein
playing a pivotal role during intestinal inflammation,
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since it orchestrates proinflammatory signals [11,12].
Aberrant expression and release of S100B correlate with
the inflammatory status of the gut. S100B accumulates
at the RAGE (receptor for advanced glycation end pro-
ducts) site only in micromolar concentrations [11,13-15]
and such interaction leads to mitogen-activated protein
kinase (MAPK) phosphorylation and consequent nuclear
factor-kappaB (NF-κB) activation, which, in turn, promote
the transcription of different cytokines and inducible nitric
oxide synthase (iNOS) protein [14]. Molecular targeting of
S100B protein during intestinal inflammation might there-
fore represent an innovative approach to treat UC.
Pentamidine isethionate, discovered to have antiproto-
zoal activity in 1938, and approved in the United States
for the treatment of Pneumocystis carinii pneumonia
and other protozoal diseases [16], appears to be an in-
triguing candidate. In addition to its antiprotozoal activ-
ity, pentamidine has been reported to inhibit S100B
activity because of its ability to block the interaction at
the Ca++/p53 site of the protein [17].
Based on this background, the present study was
aimed at evaluating the beneficial effect of a daily ad-
ministration of pentamidine in an acute model of UC
induced by dextran sulphate sodium (DSS) administra-
tion in drinking water in CD-1 mice. DSS-induced colitis
is highly reproducible and is a well-known in vivo model
of experimental colitis in rodents that reproduces many
features of UC [18]. We tested the effect of pentamidine
on (i) intensity of the symptoms (diarrhea, blood in the
feces, animal weight loss) through a disease activity index
(DAI) scale [19]; (ii) release of cytokines and proinflamma-
tory signaling molecules present in mice plasma; (iii) post-
mortem evaluation of macroscopic shortening of large
intestine and spleen weight; (iv) global colonic inflamma-
tion by the evaluation of biochemical and histological
changes of the tissue.
Methods
Animals and experimental design
Six-weeks-old male CD-1 mice (25 to 35 g; Harlan La-
boratories, Udine, Italy) were used for the experiments.
Animals were randomly divided into five groups (n = 10
each): noncolitic control group; colitic group; colitic
group receiving daily pentamidine 0.8 mg/kg; colitic group
receiving daily pentamidine 4 mg/kg; noncolitic group
receiving daily pentamidine 4 mg/kg (as drug internal
control). Colitis was induced by administrating DSS
(4% w/v, MW 36,000 to 50,000) in drinking water for six
consecutive days (starting from day 1), as described in
Figure 1A. Pentamidine was given intraperitoneally
starting at day 2 through day 6. At day 7, animals were
sacrificed and tissues were removed to perform macro-
scopic, histochemical and biochemical analyses as
described below.
Disease activity index (DAI)
The DAI scale is based on the evaluation of different
parameters characterizing experimental colitis induction
and progression. Body weight, presence of gross blood in
the feces and stool consistency were recorded daily
(from day 0 to 7) by an observer blinded to the treat-
ment. According to the criteria proposed by Cooper
et al. [19], the DAI was determined by scoring changes
in: weight loss (0 = none; 1 = 1 to 5%; 2 = 5 to 10%; 3 =
10 to 20%; 4 = >20%); stool consistency (0 = normal; 2 =
loose; 4 = diarrhea) and rectal bleeding (0 = normal; 2 =
occult bleeding; 4 = gross bleeding). At the end of the
experiment, mice were sacrificed and colons and spleens
were isolated to measure the length and weight of colon
and spleen, respectively.
Preparation of cytosolic extracts and western blot
analysis
Removed colonic tissues were processed for western blot
analysis. Briefly, after homogenization in ice-cold hypo-
tonic lysis buffer, protein concentration was determined
using Bio-Rad protein assay kit (Bio-Rad, Milan, Italy).
Analysis of cyclooxigenase (COX)-2, iNOS, TNF-α, S100B,
glial fibrillary acidic protein (GFAP), phosphorylated-p38
(p-p38) MAPK, p50, p65 and β-actin protein expression
was performed on total protein fractions of homogenates.
Equivalent amounts (50 μg) of each homogenate under-
went electrophoresis through a polyacrilamide minigel.
Proteins were then transferred onto nitrocellulose mem-
brane that were saturated by incubation with 10% nonfat
dry milk in 1× PBS overnight at 4°C and then incubated
with either mouse anti-S100B (1:200 v/v, Neo-Marker,
Milan, Italy), mouse anti-iNOS (1:2000 v/v, BD Bios-
ciences, Milan, Italy), rabbit anti-COX-2 (1:250 v/v, BD
Biosciences), GFAP (1:5000 v/v, Abcam, Cambridge, UK),
mouse anti-p50, mouse anti-p65 (1:1000 v/v, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), or mouse anti-β-
actin (1:1,000 v/v, Santa Cruz Biotechnology) for 2 h at
room temperature (RT). Membranes were then incubated
with anti-mouse or anti-rabbit immunoglobulins coupled
to peroxidase (1:2000 v/v, Dako, Milan, Italy). Immune
complexes were revealed by using enhanced chemilumin-
escence detection reagents (Amersham Biosciences, Milan,
Italy) and exposed to Kodak X-Omat film (Eastman Kodak
Co., Rochester, NY, USA OK). Protein bands were then
scanned and densitometrically analyzed with a GS-700 im-
aging densitometer.
Preparation of blood samples
Before being sacrificed, mice were deeply anesthetized
and the blood was taken by cardiac puncture and col-
lected in 5% EDTA vials. To determine nitric oxide
(NO), prostaglandin E2 (PGE2), IL-1β, TNF-α, and S100B
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levels, plasma was isolated from the blood, immediately
frozen, and stored at −80°C until the assays.
Plasma NO quantification
NO was measured as nitrite (NO2
-) accumulation in plasma.
A spectrophotometer assay based on the Griess reaction
was used [20]. Briefly, Griess reagent (1% sulphanilamide,
0.1% naphthylethylenediamine in H3PO4) was added to an
equal volume of plasma and the absorbance was measured
at 550 nm. NO2
- concentration (nM) was thus determined
using a standard curve of NaNO2.
Plasma PGE2, TNF-α, S100B, and IL-1β quantification
Quantitative determination of PGE2, IL-1β, TNF-α,
and S100B was carried out performing enzyme linked-
immunosorbent assay (ELISA) on plasma samples
(PGE2, TNF-α, IL-1β kits were from Invitrogen, Milan,
Italy; S100B kit was from BioVendor, Heidelberg,
Germany) according to the manufacturer’s kit instructions.
Macrophage infiltration in the mucosa
Samples for immunohistochemical assessment were iso-
lated from distal colon and fixed in 4% paraformaldehyde,
Figure 1 (A) Dextran sulphate sodium (DSS)-exposed (4%) mice were treated daily with 0.8 mg/kg or 4 mg/kg pentamidine given
intraperitoneally. Effect of pentamidine on (B) DAI score, (C) colonic length and (D) spleen weight in DSS-treated mice. Results are expressed as
mean ± SEM of n = 5 experiments. ***P <0.001 vs. vehicle (saline); °P <0.05; °°P <0.01 and °°°P <0.001 vs. DSS. DAI, disease activity index.
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embedded in paraffin, sectioned in 15 μm slices and
processed for immunohistochemistry. Slices were pre-
treated for 20 min using heat-mediated antigen retrieval
with a sodium citrate buffer, incubated with MAC387 [21]
(1 μg/ml, Abcam) for 15 min at RT, and detected using
horseradish peroxidase (HRP)-conjugated compact poly-
mer system. DAB was used as the chromogen. Slices were
then counterstained with hematoxylin, mounted with
Eukitt and analyzed with a microscope (Nikon Eclipse 80i
by Nikon Instruments Europe, Amstelveen, Netherlands).
Images were captured by a high-resolution digital camera
(Nikon Digital Sight DS-U1).
p53 Immunofluorescence
Colon slices derived from both control and treated mice
were blocked in 10% bovine serum albumin 0.1%
Triton-PBS solution for 90 min at RT and subsequently
stained for 1 h at RT with anti-p53 antibody (1:1250,
Santa Cruz Biotechnology) and anti-MAC387 (1:200,
Abcam). Sections were then incubated for 1 h at RT in
the dark with the proper secondary antibody: fluorescein
isothiocyanate-conjugated anti-rabbit (1:100, Abcam) or
Texas Red-conjugated anti-mouse (1:64, Abcam), re-
spectively. Nuclei were stained with Hoechst (1:5000,
Sigma-Aldrich, Milan, Italy). Slides were thus analyzed
with a microscope (Nikon Eclipse 80i by Nikon Instru-
ments Europe), and images were captured at 10X and
20X magnification by a high-resolution digital camera
(Nikon Digital Sight DS-U1).
Myeloperoxidase (MPO) assay
MPO, a marker of polymorphonuclear leukocyte accu-
mulation and general inflammation occurring in colonic
tissue, was determined as previously described [22].
After removal, colonic tissue was rinsed with cold saline,
opened and deprived from the mucosa using a glass
slide. The resulting layer was then homogenized in a so-
lution containing 0.5% hexadecyltrimethylammonium
bromide dissolved in 10 mM potassium phosphate buf-
fer (pH 7.0) and centrifuged for 30 min at 20000 × g at
37°C. An aliquot of the supernatant was mixed with a
solution of tetramethylbenzidine (1.6 mM) and 0.1 mM
H2O2. The absorbance was then spectrophotometrically
measured at 650 nm. MPO activity was determined as
the amount of enzyme degrading 1 mmol of peroxide
per minute at 37°C and was expressed in milliunits per
100 mg of wet tissue weight.
Lipid peroxidation assay
Malonyl dialdehyde (MDA) was measured by the thio-
barbituric acid colorimetric assay [23] in colonic tissue.
Briefly, 1 mL 10% (w/v) trichloroacetic acid was added
to 450 μl of tissue lysate. After centrifugation, 1.3 mL
0.5% (w/v) thiobarbituric acid was added and the
mixture was heated at 80°C for 20 min. After cooling,
MDA formation was recorded (absorbance 530 nm and
absorbance 550 nm) in a Perkin Elmer (Waltham, MA,
USA) spectrofluorimeter and the results were presented
as ng MDA/mL.
Mucosa and LMMP preparations
In order to further evaluate the putative site and the
mechanism of action of pentamidine, additional experi-
ments were set up as follows. Colonic segments (ap-
proximately 1.5 cm long) were isolated from another set
of CD-1 mice not previously used for any in vivo treat-
ment. Mice were euthanized by injection of pentobar-
bital sodium (100 mg/kg) and distal colon was removed
and cut longitudinally to expose the mucosa. Under ster-
ile conditions, the tissues were placed in Dulbecco’s
modified Eagle's medium (supplemented with 5% fetal
bovine serum, 2 mM glutamine, 100 U/mL penicillin,
100 μg/mL streptomycin, all from Invitrogen), pinned
flat and the mucosa was carefully peeled off to obtain
the longitudinal muscle-myenteric plexus (LMMP) layer
[24]. Depending upon the experimental plan, both mu-
cosa and LMMP were stimulated for 24 h with exogen-
ous lipopolysaccharide (LPS) (10 μg/ml) + DSS (1% w/v)
or exogenous S100B (5 μM, Sigma-Aldrich, Milan, Italy),
with or without the addition of pentamidine (0.5 to
5 μM) administered to the tissue 10 min prior to LPS +
DSS or S100B stimulus.
Statistical analysis
Results were expressed as mean ± SEM of experiments.
Statistical analysis was performed using parametric one-
way analysis of variance (ANOVA) and multiple com-
parisons were performed by Bonferroni's post hoc test.
P values <0.05 were considered significant.
Results
Pentamidine ameliorates DAI score, preserves colonic
length and reduces splenomegaly induced by DSS
Starting from day 4 after DSS administration, DAI score
was significantly increased in DSS groups. As expected,
DSS caused a consistent increase in bloody diarrhea to-
gether with loss of body weight, as compared to control
group (Figure 1B). DSS also caused a significant shorten-
ing of colon and a marked increase of spleen weight
(Figure 1C and D). Pentamidine treatment inhibited the
rise in DAI score in a dose-dependent way, suggesting
an overall improvement of intestinal symptoms asso-
ciated with colitis after DSS administration; such effect
was accompanied by a reduction of bloody stools, diar-
rhea frequency, and a rescue of body weight (Figure 1B).
Moreover, pentamidine was able to preserve colonic
length and to prevent splenomegaly in DSS-treated mice
(Figure 1C and D).
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Pentamidine inhibits intestinal inflammation induced by
DSS
In Figure 2 it is shown that the administration of DSS
caused a marked increase of iNOS, COX-2, S100B and
GFAP protein expression compared to control mice. Pent-
amidine treatment resulted in a dose-dependent attenu-
ation of iNOS, COX-2 and GFAP but not of S100B
protein overexpression (Figure 2A and B). As expected,
Griess reaction and ELISA demonstrated that the admin-
istration of DSS caused a significant increase in plasma
NO2
- level, PGE2, IL-1β, TNF-α and S100B, compared to
control mice (Figure 3). Also in this case and according to
western blot results, pentamidine treatment caused a
marked and dose-dependent attenuation of all the inflam-
matory mediators in plasma, except for S100B release that
remained unaffected after pentamidine treatment.
Pentamidine inhibits S100B-induced lipid peroxidation,
p38 MAPK phosphorylation, and NF-κB activation induced
by DSS
Further characterizing the inhibitory effect of pentami-
dine, we found that in DSS-treated mice the increase
in S100B expression was accompanied by a significant
increase in lipid peroxidation and phosphorylation of
p38 MAPK (Figure 4A and B). These effects were
related to both p50 and p65 protein overexpression
and indicated the activation of NF-κB (Figure 4B). In
our experimental conditions, pentamidine significantly
and dose-dependently inhibited MDA accumulation,
p38 MAPK phosphorylation and, consequently, NF-κB
activation.
Pentamidine reduces DSS-induced macrophage
infiltration and MPO activity
Colonic mucosa was extensively infiltrated by macro-
phages in DSS-treated mice compared to control mice
(Figure 5A and B). Such increase was accompanied as
well by neutrophil infiltration, as showed by the increased
MPO activity (Figure 5C). Pentamidine treatment caused
a significant and dose-dependent reduction in macro-
phage infiltration together with significant and dose-
dependent inhibition of MPO activity, indicating that
pentamidine is able to control neutrophil infiltration in
colonic tissues (Figure 5A and B).
Figure 2 (A) Western blot analysis showing the effect of pentamidine on iNOS, COX-2, GFAP and S100B protein expression in colonic
tissue of DSS-treated mice; (B) relative quantification of immunoreactive bands (arbitrary units). Results are expressed as mean ± SEM of
n = 5 experiments performed in triplicate. ***P <0.001 vs. vehicle (saline); °°P <0.01 and °°°P <0.001 vs. DSS. COX2, cyclooxigenase-2; DSS, dextran
sodium sulphate; GFAP, glial fibrillary acidic protein; iNOS, inducible nitric oxide synthase.
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Pentamidine induces p53 expression in infiltrating
macrophages
Macrophage infiltration in the colonic tissues from
DSS-treated mice was confirmed by immunofluorence
(Figure 6A). Pentamidine treatment significantly and dose-
dependently reduced macrophage infiltration (Figure 6A).
Very interestingly, such decrease was accompanied by the
reverse trend in p53 expression. In fact, p53 resulted nega-
tive in the colon from control and DSS-treated mice, while
a strong immunopositivity was found in colonic tissues
from pentamidine-treated mice (Figure 6). Moreover, p53
expression was found in macrophages, as revealed from
the co-expression with MAC387, a specific macrophage
marker [21] (Figure 6).
S100B-dependent effect of pentamidine
An internal check for the expression of S100B protein
was performed in both mucosal and LMMP preparations
confirming that the protein was expressed exclusively in
the LMMP layer (Figure 7A). Preparations were separ-
ately challenged with DSS (1%) plus LPS (1 μg/ml) or
S100B (5 μM) in the presence or absence of pentamidine
(0.5 to 5 μM). Stimulation with LPS + DSS caused a
marked proinflammatory response in the mucosa as well
as in LMMP preparations, as demonstrated by the in-
crease in nitrites level, PGE2 and TNF-α level compared
to respective nonstimulated preparations (Figure 7B and
C). Very interestingly, pentamidine had no significant
beneficial effect on the mucosa while it significantly and
Figure 3 Effect of pentamidine on the release of inflammatory mediators (NO2
- , PGE2, IL-1β, TNF-α) and S100B in plasma of
DSS-treated mice. Results are expressed as mean ± SEM of n = 5 experiments performed in triplicate. ***P <0.001 vs. vehicle (saline); °°P <0.01
and °°°P <0.001 vs. DSS. DSS, dextran sodium sulphate; IL-1β, interleukin-1 beta; NO, nitric oxide; PGE2, prostaglandin E2; TNF-α, tumor necrosis
factor alpha.
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concentration-dependently reduced the release of nitrites,
PGE2 and TNF-α in LMMP preparations (Figure 7C). Ex-
ogenous application of S100B to the mucosa caused a
significant increase in nitrites, PGE2, and TNF-α level
(Figure 7B). As confirmation for the S100B-dependent
effect, pretreatment with pentamidine significantly and
concentration-dependently reduced S100B-induced in-
flammation in the mucosa (Figure 7C).
Discussion
The results of the present study indicate that pentami-
dine is capable to profoundly and beneficially impact on
an animal model of acute colitis. The model we used has
been demonstrated to resemble UC features [18]. Pre-
vailing therapies for UC include chronic administration
of glucocorticosteroids and mesalamine [25,26]. Steroids
are effective in the short-term treatment of acute flares
of UC but they are not suitable as a maintenance ther-
apy due to a variety of systemic adverse reactions [27].
Sulfasalazine and its derivative 5-aminosalicylic acid are
effective only in mild-to-moderate acute phase of the
disease and in preventing relapse. Biological drugs such
as monoclonal anti-TNF-α antibody (infliximab and ada-
limumab) have been recently introduced in the therapy
of relapsing inflammatory bowel disease with encour-
aging results in the maintenance of remission [28]. How-
ever, the long-term safety of these drugs, the possibility
to induce severe side effects [29-31] together with the
high costs of the therapy for the patients warrant novel
and alternative pharmacological approaches.
We demonstrated that pentamidine efficiently and
dose-dependently improved colitis. It caused attenuation
of the DAI together with preservation of colonic length
and reduction of splenomegaly induced by DSS-colitis.
Besides inducing such macroscopic beneficial effects,
treatment with pentamidine also resulted in microscopic
amelioration of intestinal inflammation as demonstrated
by the reduction of MPO activity, a marker of tissue
neutrophils activation, and of macrophage mucosal infil-
tration. Very interestingly, we found that the treatment
with pentamidine induced p53 expression on infiltrating
macrophages. We know that S100B inhibits p53 activity
and that pentamidine inhibits S100B overexpression.
Thus, we may speculate that pentamidine, through the
Figure 4 (A) Effect of pentamidine on MDA production in colonic tissue of DSS-treated mice; (B) immunoblots showing the effect of
pentamidine on p-p38 MAPK, p50 and p65 protein expression in colonic tissue of DSS-treated mice; (C) relative quantification of
immunoreactive bands. Results are expressed as mean ± SEM of n = 5 experiments performed in triplicate. ***P <0.001 vs. vehicle (saline);
°P <0.05, °°P <0.01 and °°°P <0.001 vs. DSS. DSS, dextran sodium sulphate; MDA, malondialdehyde; p-p38 MAPK, phosphorylated-p38 MAPkinase.
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inhibition of S100B, induces p53 expression indirectly
driving macrophages apoptosis. This trend could also ex-
plain the anti-inflammatory effect exerted by pentamidine.
As expected, DSS treatment caused a marked increase
in COX-2 and iNOS protein expression in the colon
accompanied by a significant release of PGE2 and NO in
the plasma. Such increase was significantly and dose-
dependently reduced by pentamidine treatment. We pre-
viously demonstrated that during intestinal inflammation,
S100B rises up to micromolar concentrations, further
amplifying inflammatory responses [6,8,12]. In these con-
ditions, S100B induces lipid peroxidation and activates
p38 MAPK phosphorylation leading, in turn, to NF-κB
activation and proinflammatory cytokines release. Here
again, we report that pentamidine treatment resulted in a
significant inhibition of lipid peroxidation, p38MAPK acti-
vation and relative stabilization of NF-κB in the cytoplasm
by targeting S100B activity. These results further confirm
that pentamidine, by interfering at the p53 binding site on
S100B protein, drastically reduces inflammatory events
induced by S100B, leading to the overall improvement of
intestinal inflammation.
Given the well-described inhibitory effect exerted by
pentamidine on S100B activity [17], we evaluated
whether it could negatively control enteric gliosis, thus
exerting a negative modulation of intestinal inflamma-
tion. The administration of DSS demonstrated an enor-
mous increase of both S100B and GFAP protein
expression. Pentamidine was not capable of negatively
modulating S100B protein expression in tissues and its
release in plasma, while it was able to induce a signifi-
cant decrease in GFAP protein expression. This data
could be explained by the fact that since pentamidine
inhibits the activity but not the expression/release of
S100B [17], this drug may prevent the downstream
effects due to the over-release of S100B during intestinal
inflammation. In an autocrine manner, S100B induces
proliferation of glial cells and, thus, increase in GFAP
expression. We can thus speculate that pentamidine,
by the inhibition of S100B activity, may control glial
proliferation as highlighted by the decrease in GFAP
expression. Alternatively, the ability of pentamidine to
significantly reduce the expression of GFAP may be
secondary to the reduced levels of inflammatory
Figure 5 (A) Effect of pentamidine on macrophage infiltration in colonic tissue of DSS-treated mice: pentamidine dose-dependently
reduced macrophages infiltration. Arrows indicate MAC387 immunopositive macrophages infiltrating colon criptae; (B) Quantification of
MAC387 immunopositive macrophages in colon criptae. Data are expressed as mean ± SEM of n = 3 experiments; (C) effect of pentamidine on
MPO level in colonic tissue of DSS-treated mice. Results are expressed as mean ± SEM of n = 6 experiments. ***P <0.001 vs. vehicle (saline);
°°P <0.01 and °°°P <0.001 vs. DSS. Original magnification 100X. DSS, dextran sodium sulphate; MPO, mieloperoxidase.
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cytokines that have been previously demonstrated to
drive glial proliferation [32].
Since S100B release has been reported to increase
macrophage activity causing proinflammatory responses
[33], we wondered whether the anti-inflammatory effect
exerted by pentamidine on acute intestinal inflammation
could be the result of the direct targeting of S100B in
the glial network or the consequence of the indirect ef-
fect on infiltrating immune cells in the mucosa. We used
organotypic cultures of isolated mucosa or LMMP pre-
parations [24] and we challenged them with DSS plus
LPS in the presence or absence of pentamidine. Our
results demonstrated that pentamidine was able to sig-
nificantly and concentration-dependently inhibit LPS +
DSS-induced NO2
- , PGE2, IL-1β and TNF-α release in
LMMP but not in mucosal preparations. This result sug-
gests that pentamidine needs S100B to exert its anti-
inflammatory properties. To confirm such hypothesis,
Figure 6 (A) Immunofluorescence analysis of colonic tissues showing the effect of pentamidine on macrophage infiltration induced by
DSS: pentamidine dose-dependently inhibited macrophage infiltration (MAC387, red) and increased p53 expression (green) in colon
criptae. Arrows indicate MAC387/p53 co-expression; (B) relative quantification (MAC387+/p53 + area/total area percentage) of macrophage
infiltration and p53 expression in DSS-treated mice. Data are expressed as mean ± SEM of n = 3 experiments. Original magnification 200X. DSS,
dextran sodium sulphate.
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we challenged mucosa preparations with exogenous
S100B in the presence or absence of pentamidine. Inter-
estingly, we found that pentamidine significantly reversed
S100B-induced release of inflammatory mediators, thus
demonstrating that anti-inflammatory properties of pent-
amidine are dependent on S100B.
Conclusions
Pentamidine may be putatively proposed as a new drug
able to control the acute phase of intestinal inflammation,
likely by acting on glial activation and thus inhibiting the
deleterious cascade induced by S100B protein. Because of
its well-known pharmacological and toxicological profile,
Figure 7 (A) Western blot analysis showing S100B protein expression in mucosa (M) and in LMMP preparations. Effect of pentamidine
on inflammatory mediators (NO2
- , PGE2, IL-1β, TNF-α) in mucosa (B) and in LMMP (C) in the presence of different proinflammatory stimuli (LPS +
DSS or exogenous S100B depending upon the experiments). Results are expressed as mean ± SEM of n = 5 experiments. ***P <0.001 vs. vehicle
(saline); °P <0.05, °°P <0.01 and °°°P <0.001 vs. proinflammatory stimulus DSS, dextran sodium sulphate; IL-1β, interleukin-1 beta; LMMP,
longitudinal-muscle myenteric plexus; LPS, lipopolysaccharide; NO, nitric oxide; TNF-α, tumor necrosis factor alpha.
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at present, pentamidine might be regarded as a potential,
innovative, manageable, and low-cost tool against colitis.
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